Decheng Capital is a leading investment firm that provides capital and strategic support to early stage life science companies with revolutionary technologies and growth stage healthcare companies with strong market presence. We are a group of dedicated professionals with complementary expertise who have outstanding track records of building highly successful companies globally. Founded in 2012, Decheng continues to capitalize on a historic opportunity in the rapid growth of healthcare industry as well as breakthroughs in life science research. With over $2 billion in capital under management and support from some of the most prestigious LPs in the world, Decheng is poised to deliver superior returns for our investors and create value for our entrepreneur partners.

Checkmate Pharmaceuticals

Terns Pharmaceuticals

VelosBio

Sema4

Omniome

ReadCoor

Invitae

SentreHEART

Equillium

Aadi Bioscience

Alpine Immune Sciences

Apexigen

Everest Medicines

Arcus Biosciences

ARMO BioSciences

Decheng Capital

Viewport Meta

IPhone / Mobile Compatible

Google Tag Manager

HSTS

Google Analytics

Global Site Tag

Font Awesome

Mobile Non Scaleable Content

Google Universal Analytics

DigiCert SSL

Founder and Managing Director

Min Cui

Office Manager at Decheng Capital Director of Staffing at Accuragen, Inc

Jen Chandler

Finance and Administration

Jewel Wu

Venture Partner

Dan Zabrowski

Business Management

Dayton Misfeldt

Engineering

Michael Notaras

Partner

Nick Pliam

Peter Colabuono

Qiang Xu

Shengyang Jin

Nathan Pliam

Xiangmin Cui

Victor Tong

Terns Pharmaceuticals is a biopharmaceutical company that focuses on discovering therapies that will improve the global disease burden. 

Upstream Bio focuses on developing an antibody therapy for the treatment of severe asthma.

Everest Medicines is dedicated to its mission of developing and commercializing novel transformative pharmaceutical therapies for patients.

ImmPACT Bio USA is developing novel cell therapies for treating cancer.

Cue is a healthcare technology company that enables people to manage their health through actionable and connected health data.

Aclaris Therapeutics is a specialty pharmaceutical company engaged in developing dermatologic therapies.

Aadi Bioscience develops a potentially mTOR inhibitor for targeted patient populations in oncology and cardiovascular diseases.

ACELYRIN is a biopharma company that identifies, acquires, and accelerates the development and commercialization of life-changing therapies.

CG Oncology is a clinical-stage biopharmaceutical company focused on the development of oncolytic immunotherapies to combat cancer.

AnHeart Therapeutics is a developer of innovative pharmaceutical products.

Early Stage Venture Investors with Investments in Stamford, Connecticut

Venture Stage Investors with Investments in California

Early Stage Venture Investors with Investments in Texas

Investors Active in Asia-Pacific (APAC) (Top 10K)

Decheng Capital is an investment firm that provides capital and strategic support to life science companies with revolutionary technologies and growth-stage healthcare companies with a strong market presence. It is a group of dedicated professionals with complementary expertise who have outstanding track records of building highly successful companies globally. Founded in 2012, Decheng continues to capitalize on a historic opportunity in the rapid growth of the healthcare industry as well as breakthroughs in life science research. With over $2 billion in capital under management and support from some of the most prestigious LPs in the world, Decheng is poised to deliver superior returns for our investors and create value for our entrepreneur partners.

Decheng Capital Global Life Sciences Fund IV

Decheng Capital China Life Sciences USD Fund III

Decheng Capital China Life Sciences USD Fund II

Decheng Capital China Life Sciences USD Fund I

Menlo Park

California

United States

North America

Aclaris Therapeutics Announces $80 Million Private Placement

Decheng Capital Eyes $700M Raise for Fifth Life Sciences Fund as VC Heats Up

Life sciences investor Decheng Capital targets $700M for fifth fund

The Week’s 10 Biggest Funding Rounds: Wiz Lands A Billion

Nalu Medical, Inc. Closes $85 Million Series E Round

India

Asia

Bangladesh

United Kingdom

Europe

Poland

HTML5

Starfield SSL

jQuery

Symantec Email Security.Cloud

GoDaddy

Microsoft Outlook

Office 365

Apache Server

Karl Mayer is a major global company in the textile dyeing equipment industry, known for its advanced solutions and innovative products.

Karl Mayer

COSMOTEX is a prominent competitor in the textile dyeing equipment market, offering a range of advanced solutions for the global textile industry.

COSMOTEX

CHTC Fong's is a leading company in the textile dyeing equipment industry, providing advanced solutions and services for textile manufacturing processes.

CHTC Fong's

Monforts Fong's Textile Machinery is a key competitor in the textile dyeing equipment market, offering a range of advanced solutions for textile manufacturing processes.

Monforts Fong's Textile Machinery

Tong Geng is a significant player in the textile dyeing equipment industry, providing innovative solutions for textile manufacturing processes.

Tong Geng

Decheng is a technology-driven company that specializes in providing advanced solutions for the global textile industry. With a focus on innovation and sustainability, Decheng offers a range of products and services designed to enhance the efficiency and environmental friendliness of textile manufacturing processes.

news impact assignment basic	general
public peers	general	May 14, 2024 5:29 PM	8553966b
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general	Nov 25, 2024 9:06 AM	c7271318
crunchbase profile	general	Nov 25, 2024 9:49 AM	47bc91a6
li profile	general	May 14, 2024 5:29 PM	d97e9a33
translate crunchbase fundingrounds	general	Nov 25, 2024 2:03 PM	6fe06f64
peers	general
news basic	general
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:DECHENG

Decheng